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Abstract
Background: This study evaluates the existence of numerical alterations of chromosome 17 and
TP53 gene deletion in gastric adenocarcinoma. The p53 protein expression was also evaluated, as
well as, possible associations with clinicopathological characteristics.
Methods: Dual-color fluorescence in situ hybridization and immunostaining were performed in
twenty gastric cancer samples of individuals from Northern Brazil.
Results: Deletion of TP53 was found in all samples. TP53 was inactivated mainly by single allelic
deletion, varying to 7–39% of cells/case. Aneusomy of chromosome 17 was observed in 85% of
cases. Chromosome 17 monosomy and gain were both observed in about half of cases. Cells with
gain of chromosome 17 frequently presented TP53 deletion. The frequency of cells with two chr17
and one TP53 signals observed was higher in diffuse than in intestinal-type GC. Immunoreactivity
of p53 was found only in intestinal-type samples. The frequency of cells with two chr17 and two
TP53 signals found was higher in samples with positive p53 expression than in negative cases in
intestinal-type GC.
Conclusion: We suggest that TP53 deletion and chromosome 17 aneusomy is a common event
in GC and other TP53 alterations, as mutation, may be implicated in the distinct carcinogenesis
process of diffuse and intestinal types.
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Background
Gastric cancer (GC) is the fourth most frequent malig-
nancy and the second most common cause of cancer
death in the World [1]. In the State of Pará (Northern Bra-
zil), GC was the most common cause of cancer death in
2000. In Belém, State of Pará, the 5-year-survival rate is
about 9–10% [2]. A better understanding of the biology of
this neoplasia progression is crucial for the development
of better tests to early neoplasia detection and also of new
treatment strategies for GC.
Molecular events in the carcinogenesis of GC remain
largely unknown [3]. A key feature in the pathogenesis of
most GC, as in many other solid cancers, is chromosomal
instability, resulting in gains and losses of parts or even
whole chromosomes [4].
Gastrointestinal tract tumors are notorious for being diffi-
cult to be analyzed by standard cytogenetic techniques [5-
9]. Fluorescence in situ hybridization (FISH) assay allows
rapid detection of numerical genetics aberrations in inter-
phase nuclei in tumor cells. FISH assay should be used to
evaluate cell-to-cell heterogeneity in gene or loci copy
number and detect small subpopulations of genetically
aberrant cells [10]. FISH studies have shown numerical
aberrations 1, 7, 8, 9, 17, 20, X and Y to be common in GC
[[7,11-19], see also review [20]]. There are some studies in
literature concerning TP53, located at chromosome
17p13.1, and chromosome 17 (chr17) copy number alter-
ations by FISH assay in GC [[21-24], see also review [20]].
The TP53 tumor suppressor plays a pivotal role in the
coordination of the repair process or in the induction of
apoptosis. TP53 somatic alteration is described in approx-
imately 50% of human cancers, including GC [25]. Dereg-
ulation of the TP53 pathway has been shown to involve
mutations, loss of heterozygosity (LOH), increased
expression of the TP53  inhibitor HDM2, or epigenetic
silencing of the TP53 promoter [26,27].
The aim of this study was to investigate chr17 and TP53
numerical alterations in GC samples from Pará State by
dual-color FISH technique. Immunostaining for p53 pro-
tein was also evaluated. These results were correlated with
clinicopathological characteristics.
Methods
Samples
The study included 20 gastric adenocarcinoma samples.
Samples of primary tumors submitted to surgical resec-
tion were obtained from João de Barros Barreto University
Hospital (HUJBB). This study investigated cancer samples
of patients from Pará State, where there is a mixed popu-
lation composed of three main ethnic groups: Amerin-
dian, African and European [28].
Patients' age, sex and tumor anatomical sites were
obtained from tumor registries. The mean age of the
twenty patients was 55 ± 14.67 years (range 24–77). The
female/male ratio was 3:2. All samples were classified
according to Laurén [29] and tumors were staged using
standard criteria by TNM staging [30]. According to Lau-
rén's classification, 6 were diffuse type (30%) and 14 were
intestinal type (70%). Table 1 shows cases with their his-
topathological characteristics.
All patients had negative histories of exposure to either
chemotherapy or radiotherapy prior to surgery; there was
no other diagnosed cancer. An informed consent with
approval of the ethics committee of HUJBB was obtained
from the studied patients.
Fish
FISH was applied on cells fixed in methanol/acetic acid
using recently made slides according to modified proto-
cols [31]. The slides were washed in 2× saline sodium cit-
rate (SSC)/0.5% NP-40 (pH 7.0) solution and dehydrated
in 70%, 80% and 95% ethanol. To determine the chr17
and TP53 copy numbers, cells were hybridized with 10 μL
dual-color direct labeled probe (Qbiogene®, CA, USA)
specific for chr17 α-satellite and TP53 gene region, labeled
with fluorescein and rhodamine respectively. The probe
applied to the slide under a glass coverslip. The probe and
sample were denatured at 75°C for 5 minutes and. In situ
hybridization occurred at 37°C in a moist chamber over-
night. Post-hybridization washings were done and the
nuclei were counterstained with DAPI/antifade. Molecu-
lar cytogenetic analysis was carried out under an Olympus
BX41 fluorescence microscope with triple DAPI/FITC/
TRICT filter (Olympus, Japan) and the FISHView®  of
Applied Spectral Imaging®  image analysis system (ASI
Ldt., Israel). For each case, 200 interphase/metaphase
nuclei were analyzed and were scored using the Hopman's
criteria [32]. In our study, the cut-off level for interphase-
FISH was 5%. To avoid misinterpretation due to technical
error, gastric mucosal tissue (nonneoplastic) and normal
lymphocyte nuclei were used as negative control.
Immunohistochemical staining
Deparaffinized tissue sections (4 μm) were incubated
with primary monoclonal antibody p53 (DO-7, dilution
1:50, DakoCytomation, CA, USA) and secondary anti-
body followed by streptavidin-biotin-peroxidase complex
(DakoCytomation, CA, USA) as previously described
[18]. Slides were visualized with diaminobenzidine-H2O2
and counterstained with Harry's hematoxylin. The results
were interpreted using the Ozturk's et al. criteria [33]. Pos-
itive p53 expression was defined as clear nuclear staining,
whereas negative p53 immunostaining was considered
when no positive cell was seen or rare cells were stained
(less than 10% weakly stained tumor cells). A breast ade-BMC Gastroenterology 2009, 9:55 http://www.biomedcentral.com/1471-230X/9/55
Page 3 of 7
(page number not for citation purposes)
nocarcinoma sample with known p53 immunoreactivity
was used as positive control and a normal gastric mucosa
as negative control. Two pathologists evaluated the
immunostaining results independently.
Statistical analyses
Statistical analyses were performed using Fisher's exact
test and Mann-Whitney test. P value < 0.05 was consid-
ered to be statistically significant.
Results
FISH
Lymphocyte nucleus and normal gastric mucosa showed
two signals to chr17 and TP53 in 97.5% and 96.5% of
analyzed cells respectively. All cancer samples presented
numerical alterations of chr17 and TP53 gene. Normal
nuclei were observed in 50.7–88% of cells/case (Table 1).
The main TP53 alteration observed was the single allelic
deletion. This alteration was present in all cases, varying to
7–39% of cells/case (Figure 1A). Chr17 monosomy
observed in 45% of samples, ranging 5–12% of cells/case.
Chr17 gain was also detected in 45% of cases. Chr17 tri-
somy was observed in 20% of the cases in a frequency up
to 7.5% cells/case (case 19), in which 40% and 60% of
these cases showed two and one single TP53 copy number
respectively. Chr17 tetrasomy with two TP53 signals was
detected in 35% of cases in a frequency up to 9% cells/
case. Four signals to chr17 and TP53 was observed in one
case (case 2) in 13.5% of cells (Table 1).
The frequency of cells with two chr17 and one TP53 sig-
nals observed was higher in diffuse than in intestinal-type
GC (p = 0.026). Chromosome alterations were not associ-
ated with other clinicopathological characteristics.
p53 protein expression
In the present study, breast adenocarcinoma (positive
control) showed p53 overexpression and the normal gas-
tric mucosa (negative control) showed lack of p53 immu-
noreactivity.
Seventeen GC samples were analyzed by immunostain-
ing. Immunoreactivity of p53 (positive) was found in 8
cases (47%) (Figure 1B). All of these cases were intestinal-
type (8 of 12 samples). Statistical analysis showed an
association between intestinal-type GC and p53 expres-
sion (p = 0.0294). In our sample, p53 immunoreactivity
was not associated with age, gender, location and TNM
status (p > 0.05) (Table 1).
The frequency of cells with two chr17 and one TP53 sig-
nals observed was higher in samples with immunoreactiv-
ity of p53 negative than in cases with positive p53
expression (p = 0.016). In intestinal-type GC, the fre-
quency of cells with two chr17 and two TP53  signals
Table 1: Clinicopathological, immunohistochemistry and FISH results of GC samples.
FISH chr17/TP53 (%)
Case Age Sex Loc† pTNM‡ LC§ IHC 2/2 2/1 1/1 3/2 3/1 3/3 4/2 4/1 1/2 2/3 4/4 4/3 5/4 2/4
1 77 M An T2N1Mx Int + 77.5 11.0 10.0 1.0 - 0.5 - - - - - - - -
2 48 F An T4N0Mx Int - 52.2 16.0 4.1 1.2 2.4 0.6 8.2 - - - 13.5 1.8 - -
3 58 M Co/an T1N1Mx Int + 68.5 14.5 4.5 - 3.0 - 3.5 2.5 1.5 0.5 - 1.5 - -
4 48 F Co/an T3N0Mx Int + 62.2 15.6 10.0 3.2 0.5 - 6.5 1.0 - 0.5 0.5 - - -
52 4F C o / a nT 3 N 3 M x I n t- 5 0 . 7 3 9 . 0 9 . 6 ----- 0 . 7 - - ---
6 71 F An/py T2N0Mx Dif - 65.0 20.0 12.0 1.0 - 2.0 - - - - - - - -
7 41 F Co/an/py T4NxMx Int + 84.5 7.8 6.5 - - 0.6 0.6 - - - - - - -
8 63 F Co/an T4N3M1 Dif 0 67.0 25.0 3.0 2.0 - 1.0 - - - - 1.5 - - 0.5
9 68 F An T1N1Mx Int + 70.0 11.5 4.5 3.0 2.0 - 4.0 1.5 1.0 0.5 2.0 - - -
10 76 M An/py T3N1M1 Int - 68.0 14.0 2.0 2.0 6.0 - 5.0 0.5 2.5 - - - - -
11 41 F All T3N1M0 Dif - 54.5 29.5 - 2.0 3.5 - 9.0 0.5 0.5 0.5 - - - -
1 26 0 M A n T 3 N 2 M x I n t0 8 8 . 0 7 . 0 5 . 0 ------- - ---
13 65 M Ca/fu T3N1Mx Int 0 69.0 16.0 10.5 - 0.5 2.0 1.0 0.5 - - - - 0.5 -
14 52 M Co/ca T2N1Mx Int + 76.5 15.0 7.5 - - 0.5 0.5 - - - - - - -
15 48 M Co/an T2N1Mx Intl + 54.0 24.0 1.5 5.0 5.5 2.5 6.0 1.5 - - - - - -
16 52 F An/py T3N1Mx Int - 53.4 27.0 1.6 3.2 4.2 1.6 8.0 - - 1.0 - - - -
17 50 F An/py T4N1Mx Int + 63.0 19.0 4.0 2.0 0.5 1.0 7.5 - 2.0 1.0 - - - -
18 47 F An T2N0Mx Dif - 65.0 17.5 9.5 1.0 2.5 1.5 1.5 1.0 - - 0.5 - - -
19 74 F Co/an/py T4N1Mx Dif - 67.0 21.5 - 1.0 7.5 - 1.5 1.5 - - - - - -
20 31 M Co/an/py T3N1Mx Dif - 62.7 24.3 2.7 5.5 1.6 - 2.7 0.5 - - - - - -
† Tumor location: An = antrum; Ca = cardia; Co = corpus; Fu = fundus; Py = pylorus | ‡ TNM pathological staging | §Laurén's classification: Int = 
Intestinal; Dif = Diffuse | Immunostaining: 0 = not done; (-) without immunoreactivity; (+) with immunoreactivity.BMC Gastroenterology 2009, 9:55 http://www.biomedcentral.com/1471-230X/9/55
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Cells submitted to FISH (A) and immunohistochemistry (B) assays Figure 1
Cells submitted to FISH (A) and immunohistochemistry (B) assays. A1 (case 14), A2 (case 5) and A3 (case 6): inter-
phase nuclei presenting chr17 monosomy (green signal) with one copy of TP53 (red signal), and nuclei presenting chr17 disomy 
with one or two copies of TP53 – 1000× magnification; B1 (case 14) and B2 (case 17): tissue with nuclear p53 immunoreactivity 
(brown stain) – 400× and 100× magnification, respectively; B3 (case 6): tissue without p53 immunoreactivity – 400× magnifica-
tion.BMC Gastroenterology 2009, 9:55 http://www.biomedcentral.com/1471-230X/9/55
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found was higher in samples with positive p53 expression
than in negative cases (p = 0.027).
Discussion
Aneusomy is one of the most common findings in human
cancer. Chromosome copy number changes encompass a
continuum ranging from sporadic events to a change of
chromosome numbers with each cell division. Although
aneusomy can be detected at early stages of transforma-
tion and even in certain premalignant lesions, the degree
of numerical chromosomal aberrations generally
increases with tumor progression, and tumors with
aggressive clinical behavior are more likely to be aneu-
somy than less malignant tumors. Aneusomy has also
been found to be associated with poor treatment outcome
in cancer patients [34].
Regarding chr17 and TP53  copy number, we observed
normal nuclei in 50.7–88% of cells/case. This result cor-
roborates our previous conventional and molecular
cytogenetic studies, which demonstrated that chr17 aneu-
somy is not a frequent in GC samples of individual from
Northern Brazil [7,35,36].
There are few studies in literature concerning chr17 and
TP53 copy number alterations. Our findings corroborated
Kobayashi et al. [21] that found deletion of TP53 in 39%
of 67 tumors and all of these samples showed chr17 poly-
somy. Takahashi et al. [22] also observed that p53 signal
count was lower than the chromosome 17 signal count in
1 of 3 intestinal-type GC.
Gomyo et al. [23] demonstrated 3 or 4 signals for chr17 in
46% of 13 intestinal-type GC samples and 77% of these
cases showed TP53 deletion by FISH assay. In our sample,
45% of all cases presented 3 or 4 signals for chr17 and
TP53 deletion was detected in all cases.
Suzuki et al. [24] observed an increased of chr17 polys-
omy frequency and the incidence of TP53 deletion ranged
from 55% to 90% in ten GC samples. They also described
that TP53 deletion was significantly higher in intestinal
than in diffuse-type cancers. However, in our sample we
found TP53 deletion in up to 49% cells/case and the fre-
quency of cells with two chr17 and one TP53  signals
observed was higher in diffuse than in intestinal-type GC.
Inconsistencies regarding the frequency of TP53 deletion
in GC between our study and Suzuki et al. [24] may be
suggestive of distinct gastric carcinogenesis pathways in
different ethnic composition or differences in stage when
the analysis was done. It is widely reported that differ-
ences between carcinogenesis processes can be the result
of distinct environmental and genetic factors.
Suzuki et al. [24] also observed that chr17 monosomy was
present in 70% of 10 cases and the most frequent pattern
in these cases was the combination of one copy of chr17
and one of TP53. On the other hand, in our sample we
observed chr17 monosomy in 45% of 20 cases (cut-off
level of 5%) and the more frequent pattern was the com-
bination of two copies of chr17 with one TP53 copy by
cell.
In the present study, chr17 tetrasomy with two TP53 sig-
nals was frequently observed. We also could observe that
chr17 gain tended to be more frequently found in tumors
with higher extension (T3 or T4 stages). This finding sug-
gests that tetrasomy event is a subsequent step after gene
deletion, which could justify the higher frequency of cells
with two copies of chr17 and one TP53 copy and also the
tendency of increased level of chr17 gain in tumors with
higher extension. Galipeau et al. [37] suggested that
increased polysomy level is associated with inactivation of
the TP53 in Barrett's esophagus in vivo, supporting our
hypothesis.
Williams et al. [38] described that TP53 deletion was the
most common aberration in gastritis, intestinal metapla-
sia, dysplasia e GC by FISH assay. The author suggested
that this abnormality may exist in the initiation and pro-
gression to gastric cancer.
TP53 deletion, as well as chromosome 17 aneusomy, was
observed in all analyzed samples, despite Laurén's his-
topathologic types. However, differential p53 expression
was detected between these groups.
Increased immunostaining of p53 can depend on either
increased synthesis of wild-type protein or accumulation
of mutated protein in the cell, since the antibody recog-
nizes both types of the protein [39]. In the present study,
we observed an increased frequency of immunostained
nuclei and the greater staining intensity in 47% of GC
samples, as compared to normal gastric mucosa. We sug-
gest that the p53 overexpression may be related to the
mutated type of this protein. The frequency of p53 overex-
pression in GC has been described varying from 19% to
57.5% of cases [23,40-44] and some studies also
described TP53 mutations related with its protein overex-
pression [23,41].
In the present study, only intestinal-type GC presented
p53 immunoreactivity. Our research suggests that, beside
TP53 loss by allelic deletion or chr17 aneusomy, a muta-
tion in the remaining TP53 allele may exist in intestinal-
type GC samples, which would explain the protein immu-
noreactivity. On the other hand, two possibilities might
be considered to the absence of immunoreactivity in dif-
fuse-type GC: this absence was not due to mutations inBMC Gastroenterology 2009, 9:55 http://www.biomedcentral.com/1471-230X/9/55
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TP53 gene or an eventual mutation in this gene would not
interfere in the protein accumulation. In both situations
the immunoreactivity cannot be detected.
The p53 expression was also associated with a higher fre-
quency of cells with two chr17 and two TP53 signals in
intestinal-type GC. We hypothesize that these cells may
present TP53 with mutations and this event could be
occurring earlier than allelic deletion in intestinal-type
gastric carcinogenesis. Further investigations concerning
TP53 mutations and expression should be done in larger
samples, also including early GC specimens.
Conclusion
Our findings showed that TP53  deletion and chromo-
some 17 aneusomy are common events in GC. Our results
also suggest that LOH is an important TP53 alteration in
GC. However, other TP53 alterations than allelic deletion
may be implicated in the carcinogenesis process.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RRB and MACS designed the study. ASK, ACG, DQC, ADS,
EML, MFL were involved in data collection, literature
searches, genetic and statistical analysis. MHGF, SHBR, SD
were involved in pathological analysis. PPA recruited
patients and was responsible by samples collection. ASK
wrote the first draft of the manuscript. All authors listed
have contributed to all subsequent drafts, and have
approved the final manuscript.
Acknowledgements
Supported by Financiadora de Estudos e Projetos (FINEP CT-INFRA/
FADESP) grant No. 0927-03. RRB and MACS have a PQ fellowship granted 
by Conselho Nacional de Desenvolvimento Científico e Tecnológico 
(CNPq). MFL has a fellowship granted by Fundação de Amparo a Pesquisa 
do Estado de São Paulo (FAPESP). ASK had a doctorate fellowship granted 
by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 
(CAPES) and is grateful to Hannah and Tarek for technical supports.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA Cancer J Clin 2005, 55:74-108.
2. Mortalidade por Câncer Gástrico no Estado do Pará, 1980–
1997.  In Arq Gastroenterol Volume 43. Edited by: Resende ALS, Mattos
IE, Koifman S. DATASUS/Ministério da Saúde, Brasil, Informações de
saúde; 2006:247-52. 
3. Kimura Y, Noguchi T, Kawahara K, Kashima K, Daa T, Yokoyama S:
Genetic alterations in 102 primary gastric cancers by com-
parative genomic hybridization: gain of 20q and loss of 18q
are associated with tumor progression.  Mod Pathol 2004,
17:1328-37.
4. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in
human cancers.  Nature 1998, 396:643-9.
5. Ferti-Passantonopoulou AD, Panani AD, Vlachos JD, Raptis SA:
Common cytogenetic findings in gastric cancer.  Cancer Genet
Cytogenet 1987, 24:63-73.
6. Xia JC, Lu S, Geng JS, Fu SB, Li P, Liu QZ: Direct chromosome
analysis of ten primary gastric cancers.  Cancer Genet Cytogenet
1998, 102:88-90.
7. Assumpção PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimarães AC,
Calcagno DQ, Khayat AS, Demachki S, Smith Mde A, et al.: Numer-
ical aberrations of chromosome 8 detected by classic cytoge-
netic and Fluorescence in situ Hybridization in individuals
from Northern Brazil with gastric adenocarcinomas.  Cancer
Genet Cytogenet 2006, 169:45-9.
8. Ochi H, Douglass HO Jr, Sandberg AA: Cytogenetic studies in pri-
mary gastric cancer.  Cancer Genet Cytogenet 1986, 22:295-307.
9. Kitayama Y, Igarashi H, Sugimura H: Different vulnerability
among chromosomes to numerical instability in gastric car-
cinogenesis: stage-dependent analysis by FISH with the use
of microwave irradiation.  Clin Cancer Res 2000, 6:3139-46.
10. Kallioniemi A, Visakorpi T, Karhu R, Pinkel D, Kallioniemi OP: Gene
Copy Number Analysis by Fluorescence in Situ Hybridiza-
tion and Comparative Genomic Hybridization.  Methods 1996,
9:113-21.
11. Panani AD, Ferti AD, Avgerinos A, Raptis SA: Numerical aberra-
tions of chromosome 8 in gastric cancer detected by fluores-
cence in situ hybridization.  Anticancer Res 2004, 24:155-9.
12. van Dekken H, Pizzolo JG, Kelsen DP, Melamed MR: Targeted
cytogenetic analysis of gastric tumors by in situ hybridization
with a set of chromosome-specific DNA probes.  Cancer 1990,
66:491-7.
13. Han K, Oh EJ, Kim YS, Kim YG, Lee KY, Kang CS, Kim BK, Kim WI,
Shim SI, Kim SM: Chromosomal numerical aberrations in gas-
tric carcinoma: analysis of eighteen cases using in situ hybrid-
ization.  Cancer Genet Cytogenet 1996, 92:122-9.
14. Beuzen F, Dubois S, Flejou JF: Chromosomal numerical aberra-
tions are frequent in oesophageal and gastric adenocarcino-
mas: a study using in-situ hybridization.  Histopathology 2000,
37:241-9.
15. Fringes B, Mayhew TM, Reith A, Gates J, Ward DC: Numerical
aberrations of chromosomes 1 and 17 correlate with tumor
site in human gastric carcinoma of the diffuse and intestinal
types. Fluorescence in situ hybridization analysis on gastric
biopsies.  Lab Invest 2000, 80:1501-8.
16. Kitayama Y, Igarashi H, Watanabe F, Maruyama Y, Kanamori M, Sug-
imura H: Nonrandom chromosomal numerical abnormality
predicting prognosis of gastric cancer: a retrospective study
of 51 cases using pathology archives.  Lab Invest 2003,
83:1311-20.
17. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith
MA, Burbano RR: Aneuploidy of chromosome 8 and C-MYC
amplification in individuals from northern Brazil with gastric
adenocarcinoma.  Anticancer Res 2005, 25:4069-74.
18. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S,
Assumpção PP, Faria MH, Rabenhorst SH, Ferreira MV, et al.: Inter-
relationship between chromosome 8 aneuploidy, C-MYC
amplification and increased expression in individuals from
northern Brazil with gastric adenocarcinoma.  World J Gastro-
enterol 2006, 12:6207-11.
19. Guimarães AC, Quintana LG, Leal MF, Takeno SS, Assumpção PP,
Lima EM, Khayat AS, Chen ES, Smith MdeAC, Burbano RR: Aneu-
ploidy of chromosome 8 detected by fluorescence in situ
hybridisation in ACP01 cell line gastric adenocarcinomas.
Clin Exp Med 2006, 6:129-33.
20. Panani AD: Cytogenetic and molecular aspects of gastric can-
cer: clinical implications.  Cancer Lett 2008, 266:99-115.
21. Kobayashi M, Kawashima A, Mai M, Ooi A: Analysis of chromo-
some 17p13 (p53 locus) alterations in gastric carcinoma cells
by dual-color fluorescence in situ hybridization.  Am J Pathol
1996, 149:1575-84.
22. Takahashi Y, Nagata T, Asai S, Shintaku K, Eguchi T, Ishii Y, Fujii M,
Ishikawa K: Detection of aberrations of 17p and p53 gene in
gastrointestinal cancers by dual (two-color) fluorescence in
situ hybridization and GeneChip p53 assay.  Cancer Genet
Cytogenet 2000, 121:38-43.
23. Gomyo Y, Osaki M, Kaibara N, Ito H: Numerical aberration and
point mutation of p53 gene in human gastric intestinal meta-
plasia and well-differentiated adenocarcinoma: analysis by
fluorescence in situ hybridization (FISH) and PCR-SSCP.  Int
J Cancer 1996, 66:594-9.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2009, 9:55 http://www.biomedcentral.com/1471-230X/9/55
Page 7 of 7
(page number not for citation purposes)
24. Suzuki S, Tenjin T, Shibuya T, Tanaka S: Chromosome 17 copy
numbers and incidence of p53 gene deletion in gastric cancer
cells. Dual color fluorescence in situ hybridization analysis.
Nippon Ika Daigaku Zasshi 1997, 64:22-9.
25. Szymanska K, Hainaut P: TP53 and mutations in human cancer.
Acta Biochim Pol 2003, 50:231-8.
26. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A: TP53
and gastric carcinoma: a review.  Hum Mutat 2003, 21:258-70.
27. Hurt EM, Thomas SB, Peng B, Farrar WL: Reversal of p53 epige-
netic silencing in multiple myeloma permits apoptosis by a
p53 activator.  Cancer Biol Ther 2006, 5:1154-60.
28. Batista dos Santos SE, Rodrigues JD, Ribeiro-dos-Santos AK, Zago
MA:  Differential Contribution of Indigenous Men and
Women to the Formation of an Urban Population in the
Amazon Region as Revealed by mtDNA and y-DNA.  Am J
Phys Anthropol 1999, 109:175-80.
29. Laurén P: The two histological main types of gastric carci-
noma: diffuse and so-called intestinal-type  carcinoma. An
attempt at a histo-clinical classification.  Acta Pathol Microbiol
Scand 1965, 64:31-49.
30. Sobin LH, Wittekind CH, eds: TNM: classification of malignant
tumours.  6th edition. New York: Wiley-Liss; 2002. 
31. Pinkel D, Straume T, Gray JW: Cytogenetic analysis using quan-
titative, high-sensitivity, fluorescence hybridization.  Proc Natl
Acad Sci USA 1986, 83:2934-8.
32. Hopman AH, Ramaekers FC, Raap AK, Beck JL, Devilee P, Ploeg M
van der, Vooijs GP: In situ hybridization as a tool to study
numerical chromosome aberrations in solid bladder tumors.
Histochemistry 1988, 89:307-16.
33. Ozturk Y, Ozer E, Lebe B, Bekem O, Buyukgebiz B: Immunohisto-
chemical evaluation of p53 expression and proliferative
activity in children with Helicobacter pylori associated gas-
tritis.  J Pediatr Gastroenterol Nutr 2005, 40:467-70.
34. Duensing A, Duensing S: Guilt by association? p53 and the devel-
opment of aneuploidy in cancer.  Biochem Biophys Res Commun
2005, 331:694-700.
35. Takeno SS, Leal MF, Lisboa LC, Lipay MV, Khayat AS, Assumpção PP,
Burbano RR, Smith Mde A: Genomic alterations in diffuse-type
gastric cancer as shown by high-resolution comparative
genomic hybridization.  Cancer Genet Cytogenet 2009, 190:1-7.
36. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC,
Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-
MYC locus amplification as metastasis predictor in intesti-
nal-type gastric adenocarcinomas: CGH study in Brazil.  Anti-
cancer Res 2006, 26:2909-14.
37. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine
DS, Rabinovitch PS, Reid BJ: 17p (p53) allelic losses, 4N (G2/
tetraploid) populations, and progression to aneuploidy in
Barrett's esophagus.  Proc Natl Acad Sci USA 1996, 93:7081-4.
38. Williams L, Jenkins GJ, Doak SH, Fowler P, Parry EM, Brown TH, Grif-
fiths AP, Williams JG, Parry JM: Fluorescence in situ hybridisation
analysis of chromosomal aberrations in gastric tissue: the
potential involvement of Helicobacter pylori.  Br J Cancer 2005,
92:1759-66.
39. César AC, Borim AA, Caetano A, Cury PM, Silva AE: Aneuploidies,
deletion, and overexpression o f  T P 5 3  g e n e  i n  i n t e s t i n a l
metaplasia of patients without gastric cancer.  Cancer Genet
Cytogenet 2004, 153:127-32.
40. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G: The rela-
tionship of p53 expression to the prognosis of 418 patients
with gastric carcinoma.  Cancer 1995, 76:720-6.
41. Poremba C, Yandell DW, Huang Q, Little JB, Mellin W, Schmid KW,
Böcker W, Dockhorn-Dworniczak B: Frequency and spectrum of
p53 mutations in gastric cancer–a molecular genetic and
immunohistochemical study.  Virchows Arch 1995, 426:447-55.
42. Kim JH, Uhm HD, Gong SJ, Shin DH, Choi JH, Lee HR, Noh SH, Kim
BS, Cho JY, Rha SY, et al.: Relationship between p53 overexpres-
sion and gastric cancer progression.  Oncology 1997, 54:166-70.
43. Gürel S, Dolar E, Yerci O, Samli B, Oztürk H, Nak SG, Gülten M,
Memik F: Expression of p53 protein and prognosis in gastric
carcinoma.  J Int Med Res 1999, 27:85-9.
44. Lee DY, Park CS, Kim HS, Kim JY, Kim YC, Lee S: Maspin and p53
protein expression in gastric adenocarcinoma and its clinical
applications.  Appl Immunohistochem Mol Morphol 2008, 16:13-8.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/9/55/pre
pub